| abstract |
The present invention provides safe, stable, effective and economical vaccines based on viral expression vectors that include a parainfluenza 5 virus (PIV5) genome that includes a heterologous nucleotide sequence that expresses a heterologous polypeptide. In some embodiments, the heterologous nucleotide sequence is inserted closer to the leader than between the hemagglutinin-neuraminidase (HN) gene and the large protein (L) RNA polymerase gene of the PIVS genome. In some embodiments, the heterologous nucleotide sequence is inserted between the small hydrophobic protein (SH) gene and the hemagglutinin-neuraminidase (HN) gene of the PIV5 genome. |